Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $4.0 million.

  • Gyre Therapeutics' Free Cash Flow rose 28402.71% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 23004.04%. This contributed to the annual value of -$6.0 million for FY2024, which is 13427.91% down from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Free Cash Flow is $4.0 million, which was up 28402.71% from $1.9 million recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Free Cash Flow high stood at $42.3 million for Q4 2022, and its period low was -$24.4 million during Q1 2021.
  • In the last 5 years, Gyre Therapeutics' Free Cash Flow had a median value of -$251000.0 in 2025 and averaged -$3.0 million.
  • In the last 5 years, Gyre Therapeutics' Free Cash Flow skyrocketed by 33929.62% in 2022 and then tumbled by 43798.64% in 2024.
  • Quarter analysis of 5 years shows Gyre Therapeutics' Free Cash Flow stood at -$17.7 million in 2021, then surged by 339.3% to $42.3 million in 2022, then tumbled by 97.55% to $1.0 million in 2023, then tumbled by 359.94% to -$2.7 million in 2024, then skyrocketed by 247.31% to $4.0 million in 2025.
  • Its Free Cash Flow stands at $4.0 million for Q3 2025, versus $1.9 million for Q2 2025 and -$251000.0 for Q1 2025.